Chronic hepatitis B in adults w/ compensated liver disease w/ evidence of active viral replication, persistently elevated liver enzyme values, & histologically active disease including those resistant to lamivudine.
Nucleoside treatment-naïve patient 500 mcg once daily. Patient w/ history of hepatitis B viraemia during lamivudine therapy or w/ known resistance to lamivudine 1 mg once daily. Nucleoside treatment-naïve patient w/ renal impairment CrCl 30-49 mL/min 250 mcg once daily, CrCl 10-29 mL/min 150 mcg once daily, CrCl <10 mL/min 50 mcg once daily. Lamivudine-refractory patient w/ renal impairment CrCl 30-49 mL/min 500 mcg once daily, CrCl 10-29 mL/min 300 mcg once daily, CrCl <10 mL/min 100 mcg once daily. Patient receiving hemodialysis Give appropriate dose after each dialysis session.
Reports of severe exacerbation of hepatitis B after stopping treatment. Closely monitor hepatic function w/ both clinical & lab follow-up for several mth after discontinuation. Women of childbearing potential should use effective contraception. Not be used during pregnancy unless clearly necessary. Discontinue breast-feeding during treatment.
Co-administration w/ medicinal products that reduce renal function or compete for active tubular secretion may increase serum conc of either entecavir or the concomitant medicinal product.
J05AF10 - entecavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Sign Out
